Zogenix Pursues Development of Abuse Deterrent Formulations of Zohydro(TM) ER With Altus Formulation
November 01, 2013 16:34 ET
|
Zogenix
SAN DIEGO, Nov. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Receives FDA Approval for Zohydro(TM) ER (hydrocodone bitartrate) Extended-Release Capsules
October 25, 2013 17:01 ET
|
Zogenix
SAN DIEGO, Oct. 25, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Provides Update on Zohydro(TM) ER NDA
October 01, 2013 18:40 ET
|
Zogenix
SAN DIEGO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Reports Second Quarter 2013 Financial Results
August 08, 2013 16:01 ET
|
Zogenix
Conference Call and Webcast Today, August 8, at 4:30 p.m. ET
SUMAVEL® DosePro® (sumatriptan injection) Second Quarter 2013 Highlights
Net product revenue of $8.9 million, up 11%...
Zogenix Announces Conference Call and Webcast to Present Second Quarter 2013 Financial Results
August 05, 2013 07:30 ET
|
Zogenix
SAN DIEGO, Aug. 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Begins Promotion of Migranal(R) Nasal Spray
August 01, 2013 07:30 ET
|
Zogenix
SAN DIEGO, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix and Valeant Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Migranal(R) Nasal Spray
June 27, 2013 11:15 ET
|
Zogenix
SAN DIEGO, June 27, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Launches Improved Migraine Toolbox in Conjunction With National Migraine Awareness Month
June 25, 2013 07:30 ET
|
Zogenix
SAN DIEGO, June 25, 2013 (GLOBE NEWSWIRE) -- In conjunction with National Migraine Awareness Month and in recognition of the significant unmet needs of migraine sufferers, Zogenix, Inc. (Nasdaq:ZGNX)...
Zogenix Announces Initiatives to Reach Key Business Milestones
June 05, 2013 08:00 ET
|
Zogenix
SAN DIEGO, June 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix and Battelle to Present Positive, New Data Demonstrating Value of Needle-Free Injection for Biologics
May 20, 2013 07:30 ET
|
Zogenix
SAN DIEGO and COLUMBUS, Ohio, May 20, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle Memorial Institute today announced new data supporting the value of the DosePro®...